{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:14:43Z","timestamp":1793873683366,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170215"],"award-info":[{"award-number":["No. 82170215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82200241"],"award-info":[{"award-number":["No. 82200241"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82270178"],"award-info":[{"award-number":["No.82270178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81970161"],"award-info":[{"award-number":["No.81970161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Projects","award":["No. 2021YFC2500300-2021YFC2500302"],"award-info":[{"award-number":["No. 2021YFC2500300-2021YFC2500302"]}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["No.2019B020236004"],"award-info":[{"award-number":["No.2019B020236004"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapsed or refractory acute myeloid leukemia (R\/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringtonine (VAH) regimen for R\/R AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This phase 2 trial was done at ten hospitals in China. Eligible patients were R\/R AML (aged 18\u201365\u00a0years) with an Eastern Cooperative Oncology Group performance status of 0\u20132. Patients received venetoclax (100\u00a0mg on day 1, 200\u00a0mg on day 2, and 400\u00a0mg on days 3\u201314) and azacitidine (75\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1\u20137) and homoharringtonine (1\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1\u20137). The primary endpoint was composite complete remission rate [CRc, complete response (CR) plus complete response with incomplete blood count recovery (CRi)] after 2 cycles of treatment. The secondary endpoints include safety and survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May 27, 2020, and June 16, 2021, we enrolled 96 patients with R\/R AML, including 37 primary refractory AML and 59 relapsed AML (16 relapsed after chemotherapy and 43 after allo-HSCT). The CRc rate was 70.8% (95% CI 60.8\u201379.2). In the patients with CRc, measurable residual disease (MRD)-negative was attained in 58.8% of CRc patients. Accordingly, overall response rate (ORR, CRc plus partial remission (PR)) was 78.1% (95% CI 68.6\u201385.4). At a median follow-up of 14.7\u00a0months (95% CI 6.6\u201322.8) for all patients, median overall survival (OS) was 22.1\u00a0months (95% CI 12.7\u2013Not estimated), and event-free survival (EFS) was 14.3\u00a0months (95% CI 7.0\u2013Not estimated). The 1-year OS was 61.5% (95% CI 51.0\u201370.4), and EFS was 51.0% (95% CI 40.7\u201360.5). The most common grade 3\u20134 adverse events were febrile neutropenia (37.4%), sepsis (11.4%), and pneumonia (21.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VAH is a promising and well-tolerated regimen in R\/R AML, with high CRc and encouraging survival. Further randomized studies are needed to be explored.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      clinicaltrials.gov identifier: NCT04424147.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-023-01437-1","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T11:02:09Z","timestamp":1682766129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: A Multicenter, Phase 2 Trial"],"prefix":"10.1186","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04424147","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hua","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"issue":"3","key":"1437_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bunjes DW, Zhang MJ. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"1437_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319\u201327.","journal-title":"Blood"},{"issue":"1","key":"1437_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","volume":"15","author":"S Caruso","year":"2022","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15(1):163.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1437_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, Li F, Xie D, Xiong X, Wang J, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1437_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","volume":"11","author":"X Yang","year":"2018","unstructured":"Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11(1):3.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1437_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1046\/j.1365-2141.2002.03637.x","volume":"118","author":"M Konopleva","year":"2002","unstructured":"Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol. 2002;118(2):521\u201334.","journal-title":"Br J Haematol"},{"issue":"1","key":"1437_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-021-01076-4","volume":"14","author":"R Buettner","year":"2021","unstructured":"Buettner R, Nguyen LXT, Morales C, Chen MH, Wu X, Chen LS, Hoang DH, Hernandez Vargas S, Pullarkat V, Gandhi V, et al. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J Hematol Oncol. 2021;14(1):70.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1437_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1437_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/10428194.2014.910657","volume":"56","author":"JM Bogenberger","year":"2015","unstructured":"Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, Tibes R. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56(1):226\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1437_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401\u20137.","journal-title":"Am J Hematol"},{"issue":"10","key":"1437_CR11","doi-asserted-by":"publisher","first-page":"E253","DOI":"10.1002\/ajh.25567","volume":"94","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Yang D, Pillai R, Sanchez JF, Mei M, Aribi A, Ali H, Sandhu K, Al Malki MM, Salhotra A, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253\u20135.","journal-title":"Am J Hematol"},{"issue":"11","key":"1437_CR12","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","volume":"105","author":"B Jan Philipp","year":"2020","unstructured":"Jan Philipp B, Smith G, Rong W, Robert TW, Martin ST, Amer MZ, Maximilian S. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020;105(11):2659\u201363.","journal-title":"Haematologica"},{"issue":"5","key":"1437_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.1985.3.5.617","volume":"3","author":"RP Warrell","year":"1985","unstructured":"Warrell RP, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol. 1985;3(5):617\u201321.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1437_CR14","first-page":"1189","volume":"6","author":"E Feldman","year":"1992","unstructured":"Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia. 1992;6(11):1189\u201391.","journal-title":"Leukemia"},{"issue":"10","key":"1437_CR15","doi-asserted-by":"publisher","first-page":"e0164238","DOI":"10.1371\/journal.pone.0164238","volume":"11","author":"MX Xie","year":"2016","unstructured":"Xie MX, Jiang Q, Li L, Zhu JJ, Zhu LX, Zhou D, Zheng YL, Yang XD, Zhu MY, Sun J, et al. HAG (homoharringtonine, cytarabine, G-CSF) regimen for the treatment of acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis with 2314 participants. PLoS ONE. 2016;11(10):e0164238.","journal-title":"PLoS ONE"},{"issue":"3","key":"1437_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1535-7163.MCT-05-0164","volume":"5","author":"R Tang","year":"2006","unstructured":"Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, Marie JP. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5(3):723\u201331.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1437_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY, Wang YY, Long J, Wu SF, Zhang YX, et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-kappaB repressing factor. Proc Natl Acad Sci U S A. 2019;116(6):2220\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1437_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman K, et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22(5):1138\u201349.","journal-title":"Clin Cancer Res"},{"key":"1437_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Ye J, Yang Y, Zhao Y, Shen H, Ye X, Xie W. The basic research of the combinatorial therapy of ABT-199 and homoharringtonine on acute myeloid leukemia. Front Oncol. 2021;11: 692497.","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"1437_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-138676","volume":"136","author":"GP Yu","year":"2020","unstructured":"Yu GP, Xu N, Huang F, Fan ZP, Liu H, Shi PC, Zhou HS, Wang ZX, Zhang Y, Liu QF. Combination of homoharringtonine with venetoclax and azacitidine excerts better treatment response in relapsed \/refractory acute myeloid leukemia. Blood. 2020;136(Supplement 1):26\u20137.","journal-title":"Blood"},{"issue":"4","key":"1437_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"9","key":"1437_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1437_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359\u201367.","journal-title":"Clin Ther"},{"key":"1437_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.554503","volume":"11","author":"Q Su","year":"2021","unstructured":"Su Q, Fan Z, Huang F, Xu N, Nie D, Lin D, Guo Z, Shi P, Wang Z, Jiang L, et al. Comparison of two strategies for prophylactic donor lymphocyte infusion in patients with refractory\/relapsed acute leukemia. Front Oncol. 2021;11: 554503.","journal-title":"Front Oncol"},{"issue":"4","key":"1437_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cll.2017.07.004","volume":"37","author":"J Xu","year":"2017","unstructured":"Xu J, Jorgensen JL, Wang SA. How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia? Clin Lab Med. 2017;37(4):787\u2013802.","journal-title":"Clin Lab Med"},{"issue":"5","key":"1437_CR26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, Lin R, Xu N, Xuan L, Ye J, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34(5):1433\u201343.","journal-title":"Leukemia"},{"key":"1437_CR27","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (2010)"},{"issue":"27","key":"1437_CR28","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400.","journal-title":"Stat Med"},{"issue":"10","key":"1437_CR29","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724\u201336.","journal-title":"Lancet Haematol"},{"key":"1437_CR30","doi-asserted-by":"crossref","unstructured":"Piccini M, Pilerci S, Merlini M, Grieco P, Scappini B, Bencini S, Peruzzi B, Caporale R, Signori L, Pancani F et al (2021) Venetoclax-based regimens for relapsed\/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience. J Clin Med 10(8)","DOI":"10.3390\/jcm10081684"},{"issue":"25","key":"1437_CR31","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39(25):2768\u201378.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1437_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, Wolf J, Klco JM, Mead PE, Das Gupta S, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21(4):551\u201360.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1437_CR33","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5(5):1552\u201364.","journal-title":"Blood Adv"},{"issue":"3","key":"1437_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"YW Wang","year":"2020","unstructured":"Wang YW, Tsai CH, Lin CC, Tien FM, Chen YW, Lin HY, Yao M, Lin YC, Lin CT, Cheng CL, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020;99(3):501\u201311.","journal-title":"Ann Hematol"},{"issue":"4","key":"1437_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000549","volume":"5","author":"J Feld","year":"2021","unstructured":"Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, Kremyanskaya M, Bar-Natan M, Keyzner A, Marcellino BK, et al. Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies. Hemasphere. 2021;5(4): e549.","journal-title":"Hemasphere"},{"key":"1437_CR36","unstructured":"Leukemia, Lymphoma Group, Chinese Society of Hematology Chinese Medical Association (2021) Chinese guidelines for the diagnosis and treatment of relapsed\/refractory acute myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi 42(8):624\u2013627"},{"issue":"47","key":"1437_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023265","volume":"99","author":"H Wang","year":"2020","unstructured":"Wang H, Bai J, Pei Z, Zhang B, Wang J, Lian X, Song Q. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed\/refractory acute myeloid leukemia: two case reports. Medicine (Baltimore). 2020;99(47): e23265.","journal-title":"Medicine (Baltimore)"},{"key":"1437_CR38","doi-asserted-by":"crossref","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T et al (2022) Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol JCO.22.00602","DOI":"10.1200\/JCO.22.00602"},{"issue":"2","key":"1437_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;11(2):25.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1437_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-020-01017-7","volume":"14","author":"L Xuan","year":"2021","unstructured":"Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):4.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1437_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-020-00859-5","volume":"13","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, Yang T, Wang S, Jiang Z, Xu N, et al. Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematol Oncol. 2020;13(1):18.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1437_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, Xu N, Zhang X, Zhang X, Xuan L, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1437_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178\u201384.","journal-title":"Nat Med"},{"key":"1437_CR44","doi-asserted-by":"crossref","unstructured":"Weng G, Zhang Y, Yu G, Luo T, Yu S, Xu N, Sun Z, Lin D, Deng L, Liang X et al (2022) Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med","DOI":"10.1111\/joim.13581"},{"issue":"2","key":"1437_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cncr.32534","volume":"126","author":"CX Zhang","year":"2020","unstructured":"Zhang CX, Lam SSY, Leung GMK, Tsui SP, Yang N, Ng NKL, Ip HW, Au CH, Chan TL, Ma ESK, et al. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. Cancer. 2020;126(2):344\u201353.","journal-title":"Cancer"},{"issue":"1","key":"1437_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","volume":"13","author":"LT Brinton","year":"2020","unstructured":"Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, Wasmuth R, Beaver L, Cempre C, Skinner J, et al. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):139.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1437_CR47","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, Mody V, Choo EF, Dail M, Shah NP, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106(4):1034\u201346.","journal-title":"Haematologica"},{"issue":"22","key":"1437_CR48","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao SJ, Qiao XN, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res. 2019;25(22):6815\u201326.","journal-title":"Clin Cancer Res"},{"key":"1437_CR49","doi-asserted-by":"crossref","unstructured":"R\u00f6rby E, Adolfsson J, Hultin E, Gustafsson T, Lotfi K, Cammenga J, J\u00f6nsson J-I (2021) Multiplexed single\u2010cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. Exp Hematol Oncol 10(1)","DOI":"10.1186\/s40164-021-00201-w"},{"key":"1437_CR50","doi-asserted-by":"crossref","unstructured":"Zhao J, Song Y, Liu D (2019) Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res 7(1)","DOI":"10.1186\/s40364-019-0170-2"},{"issue":"20","key":"1437_CR51","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1073\/pnas.1703476114","volume":"114","author":"YJ Dai","year":"2017","unstructured":"Dai YJ, Wang YY, Huang JY, Xia L, Shi XD, Xu J, Lu J, Su XB, Yang Y, Zhang WN, et al. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement. Proc Natl Acad Sci U S A. 2017;114(20):5237\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1437_CR52","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(8):e552\u201361.","journal-title":"Lancet Haematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01437-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T12:03:03Z","timestamp":1682769783000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01437-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01437-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with Declaration of Helsinki principles. All procedures were approved by the ethics committee review board of each participating hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}